5-HT6 receptor antagonists: Potential efficacy for the treatment of cognitive impairment in schizophrenia

Current Pharmaceutical Design

Volumn 21, Issue 26, 2015, Pages 3739-3759

  De Bruin, Natasja M W J ^a   Kruse, Chris G ^b  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

5 Hydroxytryptamine6 receptor (5 HT6R); Animal models; Clinical development; Cognition; Comorbidities; Schizophrenia

Indexed keywords

4 AMINOBUTYRIC ACID; ACETYLCHOLINE; ALCOHOL; COCAINE; DOPAMINE; GLUTAMIC ACID; IDALOPIRDINE; MAMMALIAN TARGET OF RAPAMYCIN; MONOAMINE; NERVE CELL ADHESION MOLECULE; NEUROLEPTIC AGENT; NEUROTRANSMITTER; NICOTINE; NORADRENALIN; PHOSPHOPROTEIN DARPP 32; POLYSIALYLIC ACID; PROTEIN KINASE FYN; SEROTONIN; SEROTONIN 6 ANTAGONIST; UNCLASSIFIED DRUG; SEROTONIN 6 RECEPTOR; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR;

4 AMINOBUTYRIC ACID RELEASE; ACETYLCHOLINE RELEASE; ANALGESIA (SENSORY DYSFUNCTION); ANXIETY DISORDER; ARTICLE; AVOIDANCE BEHAVIOR; BEHAVIOR ASSESSMENT; BINDING AFFINITY; BODY WEIGHT; COGNITION; COGNITIVE DEFECT; COMORBIDITY; CONDITIONING; DENTATE GYRUS; DEPRESSION; DRUG ABUSE; DRUG DEPENDENCE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; EPISODIC MEMORY; EXECUTIVE FUNCTION; EXPERIMENTAL BEHAVIORAL TEST; EXTRAPYRAMIDAL SYMPTOM; FOOD DIGGING TEST; FOOD INTAKE; GABAERGIC TRANSMISSION; HIPPOCAMPAL CA1 REGION; HUMAN; IMPULSIVENESS; INTERNEURON; LONG TERM POTENTIATION; MAZE TEST; METABOLIC DISORDER; NERVE CELL; NERVE CELL PLASTICITY; NONHUMAN; OBESITY; OPERANT SKINNER BOX TASK; PASSIVE AVOIDANCE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REACTION TIME; RECOGNITION; SCHIZOPHRENIA; SOCIAL COGNITION; SUBSTANCE ABUSE; WORKING MEMORY; ANIMAL; ATTENTION; COGNITION DISORDERS; DRUG EFFECTS; PERCEPTION; PHYSIOLOGY;

ANIMALS; ANTIPSYCHOTIC AGENTS; ATTENTION; COGNITION DISORDERS; HUMANS; MEMORY, EPISODIC; RECEPTORS, SEROTONIN; SCHIZOPHRENIA; SEROTONIN ANTAGONISTS; SOCIAL PERCEPTION;

EID: 84936955137     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612821666150605112105     Document Type: Article

References (233)

1. Ruat M, Traiffort E, Arrang J, et al. A novel rat serotonin (5-HT6) receptor: Molecular cloning, localozation and stimulation of cAMP accumulation. Biochem Biophys Res Commun 1993; 193: 268-76.
2. Monsma FJ, Shen Y, Ward RP, Hamblin MW, Sibley DR. Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Mol Pharmacol 1993; 43: 320-7.
3. Kohen R, Metcalf MA, Khan N, et al. Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor. J Neurochem 1996; 66: 47-56.
4. Gerard C, Martres M, Lefevre K, et al. Immuno-localization of serotonin 5-HT 6 receptor-like material in the rat central nervous system. Brain Res 1997; 746: 207-19.
5. Ward RP, Hamblin MW, Lachowicz JE, Hoffman BJ, Sibley DR, Dorsa DM. Localization of serotonin subtype 6 receptor messenger RNA in the rat brain by in situ hybridization histochemistry. Neuroscience 1995; 64: 1105-11.
6. Hirst WD, Abrahamsen B, Blaney FE, et al. Differences in the central nervous system distribution and pharmacology of the mouse 5-hydroxytryptamine-6 receptor compared with rat and human receptors investigated by radioligand binding, site-directed mutagenesis, and molecular modeling. Mol Pharmacol 2003; 64: 1295-308.
7. Marazziti D, Baroni S, Pirone A, et al. Distribution of serotonin receptor of type 6 (5-HT6) in human brain post-mortem. a pharmacology, autoradiography and immunohistochemistry study. Neurochem Res 2012; 37: 920-7.
8. Marazziti D, Baroni S, Pirone A, et al. Serotonin receptor of type 6 (5-HT6) in human prefrontal cortex and hippocampus post-mortem: An immunohistochemical and immunofluorescence study. Neurochem Int 2013; 62: 182-8.
9. White L, Friedman JI, Bowie CR, et al. Long-term outcomes in chronically hospitalized geriatric patients with schizophrenia: retrospective comparison of first generation and second generation antipsychotics. Schizophr Res 2006; 88: 127-34.
10. Kucharska-Pietura K, Tylec A, Czernikiewicz A, Mortimer A.Attentional and emotional functioning in schizophrenia patients treated with conventional and atypical antipsychotic drugs. Med Sci Monit 2012; 18: 44-49.
11. Potkin S. Long-term management of schizophrenia. Eur Neuropsychopharmacol 2009; 19: S720.
12. Keefe RSE, Harvey PD. Cognitive Impairment in Schizophrenia. In: Geyer MA, Gross G, Eds. Novel antischizophrenia treatments, handbook of experimental pharmacology. Berlin, Heidelberg: Springer 2012; pp. 11-38.
13. Shayegan DK, Stahl SM. Atypical antipsychotics: matching receptor profile to individual patient's clinical profile. CNS Spectr 2004; 9: 6-14.
14. Davies S, Silvestre JS, Guitart X. Drug discovery targets: 5-HT6 receptor. Drugs Future 2005; 30: 479-95.
15. Hirano K, Searle KL, Nasir S, Aw C-C, Browne ER, Rutter AR. In vivo 5-HT(6) receptor occupancy by antipsychotic drugs in the rat brain. Neurosci Lett 2011; 503: 240-3.
16. Witten L, Bang-Andersen B, Nielsen S, et al. Characterization of [3H]Lu AE60157 ([3H]8-(4-methylpiperazin-1-yl)-3-phenylsulfonylquinoline) binding to 5-hydroxytryptamine6 (5-HT6) receptors in vivo. Eur J Pharmacol 2012; 676: 6-11.
17. Raedler TJ. Comparison of the in-vivo muscarinic cholinergic receptor availability in patients treated with clozapine and olanzapine. Int J Neuropsychopharmacol 2007; 10: 275-80.
18. Raedler TJ, Knable MB, Jones DW, Urbina RA, Egan MF, Weinberger DR. Central muscarinic acetylcholine receptor availability in patients treated with clozapine. Neuropsychopharmacology 2003; 28: 1531-7.
19. Kelly DL, Conley RR, Richardson CM, Tamminga CA, Carpenter WT. Adverse effects and laboratory parameters of high-dose olanzapine vs. clozapine in treatment-resistant schizophrenia. Ann Clin Psychiatry 2003; 15: 181-6.
20. Lieberman JA. Managing anticholinergic side effects. Prim Care Companion J Clin Psychiatry 2004; 6: 20-23.
21. Arnt J, Olsen CK. 5-HT6 receptor ligands and their antipsychotic potential. In: Borisini F, Ed. Int RevNeurobiol: Pharmacology of 5-HT6 receptors. Part 2, Volume 96. New York: Academic Press 2011; pp. 141-61.
22. Leng A, Ouagazzal A, Feldon J, Higgins GA. Effect of the 5-HT6 receptor antagonists Ro04-6790 and Ro65-7199 on latent inhibition and prepulse inhibition in the rat: comparison to clozapine. Pharmacol Biochem Behav 2003; 75: 281-8.
23. Schreiber R, Vivian J, Hedley L, et al. Effects of the novel 5-HT(6) receptor antagonist RO4368554 in rat models for cognition and sensorimotor gating. Eur Neuropsychopharmacol 2007; 17: 277-88.
24. Gravius A, Laszy J, Pietraszek M, et al. Effects of 5-HT6 antagonists, Ro-4368554 and SB-258585, in tests used for the detection of cognitive enhancement and antipsychotic-like activity. Behav Pharmacol 2011; 22: 122-35.
25. Mitchell ES, Neumaier JF. 5-HT6 receptor antagonist reversal of emotional learning and prepulse inhibition deficits induced by apomorphine or scopolamine. Pharmacol Biochem Behav 2008; 88: 291-8.
26. Arnt J, Bang-Andersen B, Grayson B, et al. Lu AE58054, a 5-HT(6) antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats. Int J Neuropsychopharmacol 2010; 13: 1021-33.
27. Fijał K, Popik P, Nikiforuk A. Co-administration of 5-HT6 receptor antagonists with clozapine, risperidone, and a 5-HT2A receptor antagonist: effects on prepulse inhibition in rats. Psychopharmacology 2014; 231(1): 269-81.
28. A Randomised, Double-blind, Parallel-Group, Fixed Dose Study Exploring the Efficacy and Safety of Lu AE58054 as Augmentation Therapy to Risperidone in Patients With Schizophrenia. Clinical-Trials.gov Identifier: NCT00810667.H. Lundbeck A/S [cited 2013 Aug 3]. Available from: http: //clinicaltrials.gov/show/NCT00810667
29. Young JW, Powell SB, Risbrough V, Marston HM, Geyer MA. Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia. Pharmacol Ther 2009; 122: 150-202.
30. Young JW, Powell SB, Geyer MA. Mouse pharmacological models of cognitive disruption relevant to schizophrenia. Neuropharmacology 2013; 62: 1381-90.
31. Jones CA, Watson DJG, Fone KCF. Animal models of schizophrenia. Br J Pharmacol 2011; 164: 1162-94.
32. Carpenter WT, Koenig JI. The evolution of drug development in schizophrenia: past issues and future opportunities. Neuropsychopharmacology 2008; 33: 2061-79.
33. Arguello PA, Gogos JA. Cognition in mouse models of schizophrenia susceptibility genes. Schizophr Bull 2010; 36: 289-300.
34. Barak S, Weiner I. Putative cognitive enhancers in preclinical models related to schizophrenia: the search for an elusive target. Pharmacol Biochem Behav 2011; 99: 164-89.
35. Keeler JF, Robbins TW. Translating cognition from animals to humans. Biochem Pharmacol 2011; 81: 1356-66.
36. Pratt J, Winchester C, Dawson N, Morris B. Advancing schizophrenia drug discovery: optimizing rodent models to bridge the translational gap. Nat Rev Drug Discov 2012; 11: 560-79.
37. King M V, Marsden CA, Fone KC. A role for the 5-HT(1A), 5-HT(4) and 5-HT(6) receptors in learning and memory. Trends Pharmacol Sci 2008; 29: 482-92.
38. Fone KCF. An update on the role of the 5-hydroxytryptamine6 receptor in cognitive function. Neuropharmacology 2008; 55: 1015-22.
39. Johnson CN, Ahmed M, Miller ND. 5-HT6 receptor antagonists: Prospects for the treatment of cognitive disorders including dementia. Curr Opin Drug Discov Devel 2008; 11: 642-54.
40. Mitchell ES, Neumaier JF. 5-HT6 receptors: a novel target for cognitive enhancement. Pharmacol Ther 2005; 108: 320-33.
41. Geldenhuys WJ, Van der Schyf CJ. The serotonin 5-HT6 receptor: a viable drug target for treating cognitive deficits in Alzheimer's disease. Expert Rev Neurother 2009; 9: 1073-85.
42. Woolley ML, Marsden CA, Fone KC. 5-ht6 Receptors. Curr Drug Targets CNS Neurol Disord 2004; 3: 59-79.
43. Tulving E. Episodic memory: from mind to brain. Annu Rev Psychol 2002; 53: 1-25.
44. Dere E, Kart-Teke E, Huston JP, De Souza Silva MA.The case for episodic memory in animals. Neurosci Biobehav Rev 2006; 30: 1206-24.
45. Tulving E, Markowitsch HJ. Episodic and declarative memory: role of the hippocampus. Hippocampus 1998; 8: 198-204.
46. Dere E, Pause BM, Pietrowsky R. Emotion and episodic memory in neuropsychiatric disorders. Behav Brain Res 2010; 215: 162-71.
47. Bonner-Jackson A, Yodkovik N, Csernansky JG, Barch DM. Episodic memory in schizophrenia: the influence of strategy use on behavior and brain activation. Psychiatry Res 2008; 164: 1-15.
48. Riutort M, Cuervo C, Danion J-M, Peretti CS, Salamé P. Reduced levels of specific autobiographical memories in schizophrenia. Psychiatry Res 2003; 117: 35-45.
49. Leavitt VM, Goldberg TE. Episodic memory in schizophrenia. Neuropsychol Rev 2009; 19: 312-23.
50. Pause BM, Zlomuzica A, Kinugawa K, Mariani J, Pietrowsky R, Dere E. Perspectives on episodic-like and episodic memory. Front Behav Neurosci 2013; 7: 33.
51. Owens SF, Picchioni MM, Rijsdijk F V, et al. Genetic overlap between episodic memory deficits and schizophrenia: results from the Maudsley Twin Study. Psychol Med 2011; 41: 521-32.
52. Egan KMA, Weinberger MFB, Goldberg DRB, Kopald TEA, Mirra BEA. Magnitude of impact of executive functioning and IQ on episodic memory in schizophrenia. Biol Psychiatry 2012; 71: 545-51.
53. Achim AM, Lepage M. Episodic memory-related activation in schizophrenia: meta-analysis. Br J Psychiatry 2005; 187: 500-9.
54. DeVito LM, Eichenbaum H. Distinct contributions of the hippocampus and medial prefrontal cortex to the "what-where-when" components of episodic-like memory in mice. Behav Brain Res 2010; 215: 318-25.
55. Dere E, Huston JP, Silva MAS. Episodic-like memory in mice: Simultaneous assessment of object, place and temporal order memory. Brain Res Brain Res Protoc 2005; 16: 10-19.
56. Eacott MJ, Norman G. Integrated memory for object, place and context in rats: a possible model of episodic-like memory? J Neurosci 2004; 24: 1948-53.
57. Ennaceur A, Aggleton J. The effects of neurotoxic lesions of the perirhinal cortex combined to fornix transection on object recognition memory in the rat. Behav Brain Res 1997; 88: 181-93.
58. Ennaceur A, Meliani K. A new one-trial test for neurobiological studies of memory in rats. III. Spatial vs. non-spatial working memory. Behav Brain Res 1992; 51: 83-92.
59. Ennaceur A. One-trial object recognition in rats and mice: methodological and theoretical issues. Behav Brain Res 2010; 215: 244-54.
60. Lenz RA, Baker JD, Locke C, et al. The scopolamine model as a pharmacodynamic marker in early drug development. Psychopharmacology (Berl) 2011; 220: 97-107.
61. Snyder PJ, Bednar MM, Cromer JR, Maruff P. Reversal of scopolamine-induced deficits with a single dose of donepezil, an acetylcholinesterase inhibitor. Alzheimers Dement 2005; 1: 126-35.
62. Sherman SJ, Atri A, Hasselmo ME, Stern CE, Howard MW. Scopolamine impairs human recognition memory: data and modeling. Behav Neurosci 2003; 117: 526-39.
63. Leurent C, Duvvuri S, Raunig D, et al. A randomized, double-blind, sponsor unblinded placebo-and positive controlled study to evaluate the effects of single oral administrations of PF-04995274 on scopolamine-induced deficits in cognitive function in healthy adults Alzheimers Dement 2012; 8 (Suppl): P583.
64. Liem-Moolenaar M, Zoethout RWM, De Boer P, et al. The effects of the glycine reuptake inhibitor R213129 on the central nervous system and on scopolamine-induced impairments in psychomotor and cognitive function in healthy subjects. J Psychopharmacol 2010; 24: 1681-7.
65. Ellis JR, Ellis KA, Bartholomeusz CF, et al. Muscarinic and nicotinic receptors synergistically modulate working memory and attention in humans. Int J Neuropsychopharmacol 2006; 9: 175-89.
66. Lieben CKJ, Blokland A, Sik A, Sung E, van Nieuwenhuizen P, Schreiber R. The selective 5-HT6 receptor antagonist Ro4368554 restores memory performance in cholinergic and serotonergic models of memory deficiency in the rat. Neuropsychopharmacology 2005; 30: 2169-79.
67. de Bruin NMWJ, Prickaerts J, van Loevezijn A, et al. Two novel 5-HT6 receptor antagonists ameliorate scopolamine-induced memory deficits in the object recognition and object location tasks in Wistar rats. Neurobiol Learn Mem 2011; 96: 392-402.
68. Hirst WD, Stean TO, Rogers DC, et al. SB-399885 is a potent, selective 5-HT6 receptor antagonist with cognitive enhancing properties in aged rat water maze and novel object recognition models. Eur J Pharmacol 2006; 553: 109-19.
69. Randomised, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study of Lu AE58054 in Patients With Moderate Alzheimer's Disease Treated With Donepezil. ClinicalTrials.gov Identifier: NCT01019421.H. Lundbeck A/S[cited 2013 Aug 3]. Available from: http: //clinicaltrials.gov/show/NCT01019421.
70. Lundbeck's Lu AE58054 meets primary endpoint in large placebocontrolled clinical proof of concept study in people with Alzheimer's disease. Corporate Release No 472.H. Lundbeck A/S [cited 2013 Aug 3]. Available from: http: //investor.lundbeck.com/releasedetail.cfm?ReleaseID=677436.
71. Phase II clinical data show statistically significant improvement for Lu AE58054 as add-on to donepezil, versus donepezil alone, on cognitive symptoms of Alzheimer's disease. Corporate Release No 505 H. Lundbeck A/S [cited 2013 Aug 3]. Available from: http: //investor.lundbeck.com/releasedetail.cfm?ReleaseID=777646.
72. A Study of SB-742457, added to Donepezil for the treatment of Mild-to-moderate Alzheimer's disease. ClinicalTrials.gov Identifier: NCT00710684.GlaxoSmithKline [cited 2013 Aug 3]. Available from: http: //clinicaltrials.gov/ct2/show/NCT00710684?term=NCT00710684& rank=1.
73. Study of SB-742457 or Donepezil Versus Placebo in Subjects With Mild-to-moderate Alzheimer's Disease. ClinicalTrials.gov Identifier: NCT00708552.GlaxoSmithKline [cited 2013 Aug 3]. Available from: http: //clinicaltrials.gov/ct2/show/NCT00708552?term=NCT00708552& rank=1.
74. SB-742457 and Donepezil in Alzheimer's disease. ClinicalTrials. gov Identifier: NCT00348192 GlaxoSmithKline [cited 2013 Aug 3]. Available from: http: //clinicaltrials.gov/ct2/show/NCT00348192?term=NCT00348192& rank=1.
75. Maher-Edwards G, Zvartau-hind M, Hunter AJ, et al. Double-Blind , Controlled Phase II Study of a 5-HT6 Receptor Antagonist, SB-742457, in Alzheimer's Disease. Curr Alzheimer Res 2010; 7: 1-12.
76. King M V, Sleight AJ, Woolley ML, Topham IA, Marsden CA, Fone KCF. 5-HT6 receptor antagonists reverse delay-dependent deficits in novel object discrimination by enhancing consolidation--an effect sensitive to NMDA receptor antagonism. Neuropharmacology 2004; 47: 195-204.
77. Kendall I, Slotten HA, Codony X, et al. E-6801, a 5-HT6 receptor agonist, improves recognition memory by combined modulation of cholinergic and glutamatergic neurotransmission in the rat. Psychopharmacology (Berl) 2011; 213: 413-30.
78. King MV, Fone KCF, Shacham S, et al. Combination of subthreshold doses of Aricept and PRX-07034, a novel 5-HT6 receptor antagonist, enhances Novel Object Discrimination (NOD) memory. J Pharmacol Sci 2006; 101 (Suppl): 150.
79. Abraham R, Shanmuganathan D, Jayarajan P, et al. SUVN-623: A 5-HT6 antagonist in animal models of cognition. Abstr Soc Neurosci 2009; 886.7/FF109.
80. Vishwakarma SL, Pendharkar VV, Jayarajan P, et al. Pharmacological profile of SUVN-502: a potent and selective 5-HT6 receptor antagonist. Abstr Soc Neurosci 2005; 652.14.
81. Da Silva Costa-Aze V, Dauphin F, Boulouard M. Serotonin 5-HT6 receptor blockade reverses the age-related deficits of recognition memory and working memory in mice. Behav Brain Res 2011; 222: 134-40.
82. Ellenbroek BA, de Bruin NMWJ, van Den Kroonenburg PTJM, van Luijtelaar ELJM, Cools AR. The effects of early maternal deprivation on auditory information processing in adult Wistar rats. Biol Psychiatry 2004; 55: 701-7.
83. Slotten HA, Kalinichev M, Hagan JJ, Marsden CA, Fone KCF. Long-lasting changes in behavioural and neuroendocrine indices in the rat following neonatal maternal separation: gender-dependent effects. Brain Res 2006; 1097: 123-32.
84. Meffre J, Chaumont-Dubel S, Mannoury la Cour C, et al. 5-HT(6) receptor recruitment of mTOR as a mechanism for perturbed cognition in schizophrenia. EMBO Mol Med 2012; 4: 1043-56.
85. Geyer MA, Wilkinson LS, Humby T, Robbins TW. Isolation rearing of rats produces a deficit in prepulse inhibition of acoustic startle similar to that in schizophrenia. Biol Psychiatry 1993; 34: 361-72.
86. Marsden CA, King MV, Fone KCF. Influence of social isolation in the rat on serotonergic function and memory--relevance to models of schizophrenia and the role of 5-HT6 receptors. Neuropharmacology 2011; 61: 400-7.
87. Marcos B, Aisa B, Ramírez MJ. Functional interaction between 5-HT(6) receptors and hypothalamic-pituitary-adrenal axis: cognitive implications. Neuropharmacology 2008; 54: 708-14.
88. Lukas M, Bredewold R, Landgraf R, Neumann ID, Veenema AH. Early life stress impairs social recognition due to a blunted response of vasopressin release within the septum of adult male rats. Psychoneuroendocrinology 2011; 36: 843-53.
89. McClelland S, Korosi A, Cope J, Ivy A, Baram TZ. Emerging roles of epigenetic mechanisms in the enduring effects of early-life stress and experience on learning and memory. Neurobiol Learn Mem 2011; 96: 79-88.
90. Fone KCF, Porkess MV. Behavioural and neurochemical effects of post-weaning social isolation in rodents-relevance to developmental neuropsychiatric disorders. Neurosci Biobehav Rev 2008; 32: 1087-1102.
91. Sergi MJ, Rassovsky Y, Widmark C, et al. Social cognition in schizophrenia: relationships with neurocognition and negative symptoms. Schizophr Res 2007; 90: 316-24.
92. Hoe M, Nakagami E, Green MF, Brekke JS. The causal relationships between neurocognition, social cognition and functional outcome over time in schizophrenia: a latent difference score approach. Psychol Med 2012; 1-13.
93. Couture SM, Penn DL, Roberts DL. The functional significance of social cognition in schizophrenia: a review. Schizophr Bull 2006; 32 (Suppl): S44-S63.
94. Fanning JR, Bell MD, Fiszdon JM. Is it possible to have impaired neurocognition but good social cognition in schizophrenia? Schizophr Res 2012; 135: 68-71.
95. Wynn JK, Sugar C, Horan WP, Kern R, Green MF. Mismatch negativity, social cognition, and functioning in schizophrenia patients. Biol Psychiatry 2010; 67: 940-7.
96. Green MF, Olivier B, Crawley JN, Penn DL, Silverstein S. Social cognition in schizophrenia: recommendations from the measurement and treatment research to improve cognition in schizophrenia new approaches conference. Schizophr Bull 2005; 31: 882-7.
97. Penn DL, Sanna LJ, Roberts DL. Social cognition in schizophrenia: an overview. Schizophr Bull 2008; 34: 408-11.
98. Loiseau F, Dekeyne A, Millan MJ. Pro-cognitive effects of 5-HT6 receptor antagonists in the social recognition procedure in rats: im plication of the frontal cortex. Psychopharmacology (Berl) 2008; 196: 93-104.
99. Chan RCK, Chen EYH, Law CW. Specific executive dysfunction in patients with first-episode medication-naïve schizophrenia. Schizophr Res 2006; 82: 51-64.
100. Eisenberg DP, Berman KF. Executive function, neural circuitry, and genetic mechanisms in schizophrenia. Neuropsychopharmacology 2010; 35: 258-77.
101. Tyson PJ, Laws KR, Flowers KA, Mortimer AM, Schulz J. Attention and executive function in people with schizophrenia: Relationship with social skills and quality of life. Int J Psychiatry Clin Pract 2008; 12: 112-9.
102. Birrell JM, Brown VJ. Medial frontal cortex mediates perceptual attentional set shifting in the rat. JNeurosci 2000; 20: 4320-4.
103. Ragozzino ME, Detrick S, Kesner RP. Involvement of the prelimbic-infralimbic areas of the rodent prefrontal cortex in behavioral flexibility for place and response learning. J Neurosci 1999; 19: 4585-94.
104. Darrah JM, Stefani MR, Moghaddam B. Interaction of N-methyl-Daspartate and group 5 metabotropic glutamate receptors on behavioral flexibility using a novel operant set-shift paradigm. Behav Pharmacol 2010; 19: 225-34.
105. Hatcher PD, Brown VJ, Tait DS, et al. 5-HT6 receptor antagonists improve performance in an attentional set shifting task in rats. Psychopharmacology (Berl) 2005; 181: 253-9.
106. Rodefer JS, Nguyen TN, Karlsson J-J, Arnt J. Reversal of subchronic PCP-induced deficits in attentional set shifting in rats by sertindole and a 5-HT6 receptor antagonist: comparison among antipsychotics. Neuropsychopharmacology 2008; 33: 2657-66.
107. Mohler EG, Baker PM, Gannon KS, et al. The effects of PRX-07034, a novel 5-HT(6) antagonist, on cognitive flexibility and working memory in rats. Psychopharmacology (Berl) 2012; 220: 687-96.
108. Mohler EG, Rueter LE. 5-HT6 antagonist reversal of an MK-801 induced impairment in an operant cognitive flexibility task. Abstr Soc Neurosci2011: 679.27/DD16.
109. Idris N, Neill J, Grayson B, et al. Sertindole improves sub-chronic PCP-induced reversal learning and episodic memory deficits in rodents: involvement of 5-HT(6) and 5-HT (2A) receptor mechanisms. Psychopharmacology (Berl) 2010; 208: 23-36.
110. De Bruin NMWJ, van Drimmelen M, Kops M, van Elk J, Middelveld-van de Wetering M, Schwienbacher I. Effects of risperidone, clozapine and the 5-HT(6) antagonist GSK-742457 on PCPinduced deficits in reversal learning in the two-lever operant task in male Sprague Dawley rats. Behav Brain Res 2013; 244: 15-28.
111. Forbes NF, Carrick LA, McIntosh AM, Lawrie SM. Working memory in schizophrenia: a meta-analysis. Psychol Med 2009; 39: 889-905.
112. Silver H, Feldman P, Bilker W, Gur RC. Working memory deficit as a core neuropsychological dysfunction in schizophrenia. Am J Psychiatry 2003; 160: 1809-16.
113. Brahmbhatt SB, Haut K, Csernansky JG, Barch DM. Neural correlates of verbal and nonverbal working memory deficits in individuals with schizophrenia and their high-risk siblings. Schizophr Res 2006; 87: 191-204.
114. Da Silva Costa-Aze V, Quiedeville A, Boulouard M, Dauphin F. 5-HT6 receptor blockade differentially affects scopolamine-induced deficits of working memory, recognition memory and aversive learning in mice. Psychopharmacology (Berl) 2012; 222(1): 99-115.
115. Nirogi RV, Abraham R, Bokare A, et al. SUVN-502 in animal models of working memory. Abstr Soc Neurosci 2008; 485.21/SS46.
116. Woolley ML, Bentley JC, Sleight AJ, Marsden CA. A role for 5-ht6 receptors in retention of spatial learning in the Morris water maze. Neuropharmacology 2001; 41: 210-19.
117. Foley AG, Murphy KJ, Hirst WD, et al. The 5-HT(6) receptor antagonist SB-271046 reverses scopolamine-disrupted consolidation of a passive avoidance task and ameliorates spatial task deficits in aged rats. Neuropsychopharmacology 2004; 29: 93-100.
118. Marcos B, Chuang TT, Gil-Bea FJ, Ramirez MJ. Effects of 5-HT6 receptor antagonism and cholinesterase inhibition in models of cognitive impairment in the rat. Br J Pharmacol 2008; 155: 434-40.
119. Vishwakarma SL, Benade V, Marshal V, et al. SUVN-502 A potent 5-HT6 receptor antagonist reverses MK-801 induced amnesia and enhances brain glutamate levels. Abstr Soc Neurosci 2007; 745.5/CCC7.
120. Woods S, Clarke NN, Layfield R, Fone KCF. 5-HT(6) receptor agonists and antagonists enhance learning and memory in a conditioned emotion response paradigm by modulation of cholinergic and glutamatergic mechanisms. Br J Pharmacol 2012; 167: 436-49.
121. Zovkic IB, Sweatt JD. Epigenetic Mechanisms in Learned Fear: Implications for PTSD. Neuropsychopharmacology 2013; 38: 77-93.
122. Perez-García G, Meneses A. Oral administration of the 5-HT6 receptor antagonists SB-357134 and SB-399885 improves memory formation in an autoshaping learning task. Pharmacol Biochem Behav 2005; 81: 673-82.
123. Meneses A, Perez-Garcia G, Liy-Salmeron G, Flores-Galvez D, Castillo C, Castilloc E. The effects of the 5-HT(6) receptor agonist EMD and the 5-HT(7) receptor agonist AS19 on memory formation. Behav Brain Res 2008; 195: 112-9.
124. Demeter E, Guthrie SK, Taylor SF, Sarter M, Lustig C. Increased distractor vulnerability but preserved vigilance in patients with schizophrenia: evidence from a translational sustained attention task. Schizophr Res 2013; 144: 136-41.
125. Nuechterlein KH, Pashler HE, Subotnik KL.Translating basic attentional paradigms to schizophrenia research: reconsidering the nature of the deficits. Dev Psychopathol 2006; 18: 831-51.
126. Chudasama Y, Robbins TW. Psychopharmacological approaches to modulating attention in the five-choice serial reaction time task: implications for schizophrenia. Psychopharmacology (Berl) 2005; 174: 86-98.
127. Talpos JC, Wilkinson LS, Robbins TW. A comparison of multiple 5-HT receptors in two tasks measuring impulsivity. J Psychopharmacol 2006; 20: 47-58.
128. De Bruin NMWJ, McCreary AC, van Loevezijn A, et al. A novel highly selective 5-HT6 receptor antagonist attenuates ethanol and nicotine seeking but does not affect inhibitory response control in Wistar rats. Behav Brain Res 2013; 236: 157-65.
129. Tsai J, Rosenheck RA. Psychiatric comorbidity among adults with schizophrenia: A latent class analysis. Psychiatry Res 2013; 210(1): 16-20.
130. Blanchard JJ, Brown SA, Horan WP, Sherwood AR. Substance use disorders in schizophrenia: review, integration, and a proposed model. Clin Psychol Rev2000; 20: 207-34.
131. Green AI, Brown ES. Comorbid schizophrenia and substance abuse. J Clin Psychiatry 2006; 67: e8.
132. Batki SL, Meszaros ZS, Strutynski K, et al. Medical comorbidity in patients with schizophrenia and alcohol dependence. Schizophr Res 2010; 107: 139-46.
133. Swofford CD, Scheller-Gilkey G, Miller AH, Woolwine B, Mance R. Double jeopardy: schizophrenia and substance use. Am J Drug Alcohol Abuse 2000; 26: 343-53.
134. Awad AG. Is it time to consider comorbid substance abuse as a new indication for antipsychotic drug development? J Psychopharmacol 2012; 26: 953-7.
135. Di Chiara G, Valentini V, Fenu S. Behavioral and neurochemical pharmacology of 5-HT6 receptors related to reward and reinforcement. In: Borsini F, Ed. Int Rev Neurobiol: Pharmacology of 5-HT6 receptors. Part 2, Volume 96. New York: Academic Press 2011, pp. 111-39.
136. Gould TJ. Addiction and cognition. Addict Sci Clin Pract 2010; 5: 4-14.
137. Nyberg F. Cognitive impairments in drug addicts. In: Gonzalez-Quevedo A, Ed. Brain damage -bridging between basic research and clinics. USA: Intechopen 2012; pp. 221-44.
138. Figueroa-Guzman Y, Mueller C, Vranjkovic O, et al. Oral administration of levo-tetrahydropalmatine attenuates reinstatement of extinguished cocaine seeking by cocaine, stress or drug-associated cues in rats. Drug Alcohol Depend 2012; 116: 72-79.
139. Bonasera SJ, Chu H-M, Brennan TJ, Tecott LH. A null mutation of the serotonin 6 receptor alters acute responses to ethanol. Neuropsychopharmacology 2006; 31: 1801-13.
140. Jayarajan P, Nirogi R, Shinde A, Medapati R, Goura V, Yathavakilla SV. Effect of SUVN-A60203, a 5-HT6 antagonist on alco hol consumption and preference in rats. Abstr Soc Neurosci 2013; 448.10/JJ9.
141. Ferguson SM, Mitchell ES, Neumaier JF. Increased expression of 5-HT6 receptors in the nucleus accumbens blocks the rewarding but not psychomotor activating properties of cocaine. Biol Psychiatry 2008; 63: 207-13.
142. Fijał K, Pachuta A, McCreary AC, et al. Effects of serotonin (5-HT)6 receptor ligands on responding for cocaine reward and seeking in rats. Pharmacol Rep 2010; 62: 1005-14.
143. Frantz KJ, Hansson KJ, Stouffer DG, Parsons LH. 5-HT(6) receptor antagonism potentiates the behavioral and neurochemical effects of amphetamine but not cocaine. Neuropharmacology 2002; 42: 170-80.
144. vanGaalen MM, Schetters D, Schoffelmeer ANM, de Vries TJ. 5-HT6 antagonism attenuates cue-induced relapse to cocaine seeking without affecting cocaine reinforcement. Int J Neuropsychopharmacol 2010; 13: 961-5.
145. Valentini V, Piras G, De Luca MA, et al. Evidence for a role of a dopamine/5-HT6 receptor interaction in cocaine reinforcement. Neuropharmacology 2013; 65: 58-64.
146. De Bruin NMWJ, Kloeze BM, McCreary AC. The 5-HT6 serotonin receptor antagonist SB-271046 attenuates the development and expression of nicotine-induced locomotorsensitisation in Wistar rats. Neuropharmacology 2011; 61: 451-7.
147. Seedat S, Fritelli V, Oosthuizen P, Emsley RA, Stein DJ. Measuring anxiety in patients with schizophrenia. J Nerv Ment Dis 2007; 195: 320-4.
148. Achim AM, Maziade M, Raymond E, Olivier D, Mérette C, Roy M-A. How prevalent are anxiety disorders in schizophrenia? A meta-analysis and critical review on a significant association. Schizophr Bull 2011; 37: 811-21.
149. Wesołowska A, Nikiforuk A. Effects of the brain-penetrant and selective 5-HT6 receptor antagonist SB-399885 in animal models of anxiety and depression. Neuropharmacology 2007; 52: 1274-83.
150. Wesołowska A, Nikiforuk A, Stachowicz K. Anxiolytic-like and antidepressant-like effects produced by the selective 5-HT6 receptor antagonist SB-258585 after intrahippocampal administration to rats. Behav Pharmacol 2007; 18: 439-46.
151. Häfner H, Maurer K, Trendler G, An Der Heiden W, Schmidt M, Könnecke R. Schizophrenia and depression: challenging the paradigm of two separate diseases--a controlled study of schizophrenia, depression and healthy controls. Schizophr Res 2005; 77: 11-24.
152. Majadas S, Olivares J, Galan J, Diez T. Prevalence of depression and its relationship with other clinical characteristics in a sample of patients with stable schizophrenia. Compr Psychiatry 2012; 53: 145-51.
153. Sands JR, Harrow M. Depression during the longitudinal course of schizophrenia. Schizophr Bull 1999; 25: 157-71.
154. Wesołowska A, Nikiforuk A. The selective 5-HT(6) receptor antagonist SB-399885 enhances anti-immobility action of antidepressants in rats. Eur J Pharmacol 2008; 582: 88-93.
155. Hirano K, Piers TM, Searle KL, Miller ND, Rutter AR, Chapman PF. Procognitive 5-HT6 antagonists in the rat forced swimming test: potential therapeutic utility in mood disorders associated with Alzheimer's disease. Life Sci 2009; 84: 558-62.
156. Nasrallah H. A review of the effect of atypical antipsychotics on weight. Psychoneuroendocrinology 2003; 28 (Suppl 1): 83-96.
157. Chue P, Cheung R. The impact of weight gain associated with atypical antipsychotic use in schizophrenia. Acta Neuropsychiatr 2004; 16: 113-23.
158. Elman I, Borsook D, Lukas SE. Food intake and reward mechanisms in patients with schizophrenia: implications for metabolic disturbances and treatment with second-generation antipsychotic agents. Neuropsychopharmacology 2006; 31: 2091-120.
159. Heal DJ, Smith SL, Fisas A, Codony X, Buschmann H. Selective 5-HT6 receptor ligands: progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders. Pharmacol Ther 2008; 117: 207-31.
160. Sargent BJ, Moore NA. New central targets for the treatment of obesity. Br J Clin Pharmacol 2009; 68: 852-60.
161. Frassetto A, Zhang J, Lao JZ, et al. Reduced sensitivity to dietinduced obesity in mice carrying a mutant 5-HT6 receptor. Brain Res 2008; 1236: 140-4.
162. Svartengren J, Ohman B, Edling N, et al. The Serotonin 5-HT6 receptor antagonist BVT-5182 reduces body weight of high fat dietinduced mice. Int J Obesity 2003; 27, T1: P1-P094.
163. Svartengren J, Axelsson-Lendin P, Edling N, et al. The selective serotonin 5-HT6 receptor antagonist BVT-5182 decreases food intake and body weight in both rats and mice. Abstr Soc Neurosci 2004.
164. Shacham S, Heal D, Cheetham S, et al. PRX-07034, a potent and selective 5-HT6 receptor antagonist, reduces food intake and body weight in dietary-induced obese (DIO) rats. Abstr Soc Neurosci 2006; 62.10.
165. Bokare AM, Shanmuganathan D, Jayarajan P, Abraham R, Marshal V, Nirogi R. 5-HT6 antagonists in animal models of feeding behavior. Abstr Soc Neurosci 2008; 584.8/RR81.
166. Schiffer B, Müller BW, Scherbaum N, et al. Impulsivity-related brain volume deficits in schizophrenia-addiction comorbidity. Brain 2010; 133: 3093-103.
167. Zhornitsky S, Rizkallah E, Pampoulova T, et al. Sensation-seeking, social anhedonia, and impulsivity in substance use disorder patients with and without schizophrenia and in non-abusing schizophrenia patients. Psychiatry Res 2012; 200: 237-41.
168. Dervaux A, Laqueille X, Bourdel M-C, Olié J-P, Krebs M-O. Impulsivity and sensation seeking in alcohol abusing patients with schizophrenia. Front Psychiatry 2010; 1: 4.
169. Enticott PG, Ogloff JRP, Bradshaw JL. Response inhibition and impulsivity in schizophrenia. Psychiatry Res 2008; 157: 251-4.
170. Singh MK, Giles LL, Nasrallah HA. Pain insensitivity in schizophrenia: trait or state marker? J Psychiatr Pract 2006; 12: 90-102.
171. Potvin S, Stip E, Tempier A, et al. Pain perception in schizophrenia: no changes in diffuse noxious inhibitory controls (DNIC) but a lack of pain sensitization. J Psychiatr Res 2008; 42: 1010-6.
172. De La Fuente-Sandoval C, Favila R, Gómez-Martin D, Pellicer F, Graff-Guerrero A. Functional magnetic resonance imaging response to experimental pain in drug-free patients with schizophrenia. Psychiatry Res 2010; 183: 99-104.
173. Potvin S, Marchand S. Hypoalgesia in schizophrenia is independent of antipsychotic drugs: a systematic quantitative review of experimental studies. Pain 2008; 138: 70-78.
174. Sandkühler J. Models and mechanisms of hyperalgesia and allodynia. Physiol Rev 2009; 89: 707-58.
175. Finn DP, Fone KCF, Beckett SRG, et al. The effects of pharmacological blockade of the 5-HT6 receptor on formalin-evoked nociceptive behaviour, locomotor activity and hypothalamo-pituitaryadrenal axis activity in rats. Eur J Pharmacol 2007; 569: 59-63.
176. Castañeda-Corral G, Rocha-González HI, Araiza-Saldaña CI, Ambriz-Tututi M, Vidal-Cantú GC, Granados-Soto V. Role of peripheral and spinal 5-HT6 receptors according to the rat formalin test. Neuroscience 2009; 162: 444-52.
177. Godínez-Chaparro B, Barragán-Iglesias P, Castañeda-Corral G, Rocha-González HI, Granados-Soto V. Role of peripheral 5-HT4, 5-HT6, and 5-HT7 receptors in development and maintenance of secondary mechanical allodynia and hyperalgesia. Pain 2011; 152: 687-97.
178. Ohno Y, Imaki J, Mae Y, Takahashi T, Tatara A. Serotonergic modulation of extrapyramidal motor disorders in mice and rats: role of striatal 5-HT3 and 5-HT6 receptors. Neuropharmacology 2011; 60: 201-8.
179. Dawson LA. The central role of 5-HT6 receptors in modulating brain neurochemistry. In: Borisini F Ed. Int Rev Neurobiol: Pharmacology of 5-HT6 receptors. Part 2, Volume 96. New York: Academic Press, 2011; pp. 1-26.
180. Lacroix LP, Dawson LA, Hagan JJ, Heidbreder CA. 5-HT6 receptor antagonist SB-271046 enhances extracellular levels of monoamines in the rat medial prefrontal cortex. Synapse 2004; 51: 158-64.
181. Li Z, Huang M, Prus AJ, Dai J, Meltzer HY. 5-HT6 receptor antagonist SB-399885 potentiates haloperidol and risperidone-induced dopamine efflux in the medial prefrontal cortex or hippocampus. Brain Res 2007; 1134: 70-78.
182. Schechter LE, Lin Q, Smith DL, et al. Neuropharmacological profile of novel and selective 5-HT6 receptor agonists: WAY-181187 and WAY-208466. Neuropsychopharmacology 2008; 33: 1323-35.
183. Valentini V, Frau R, Bordi F, Borsini F, Di Chiara G. A microdialysis study of ST1936, a novel 5-HT6 receptor agonist. Neuropharmacology 2011; 60: 602-8.
184. Riemer C, Borroni E, Levet-Trafit B, et al. Influence of the 5-HT6 receptor on acetylcholine release in the cortex: pharmacological characterization of 4-(2-bromo-6-pyrrolidin-1-ylpyridine-4-sulfonyl)phenylamine, a potent and selective 5-HT6 receptor antagonist. J Med Chem 2003; 46: 1273-6.
185. Brennaman LH, Maness PF. NCAM in neuropsychiatric and neurodegenerative disorders. Adv Exp Med Biol 2010; 663: 299-317.
186. Barbeau D, Liang JJ, Robitalille Y, Quirion R, Srivastava LK. Decreased expression of the embryonic form of the neural cell adhesion molecule in schizophrenic brains. Proc Natl Acad Sci USA 1995; 92: 2785-9.
187. Van Kammen DP, Poltorak M, Kelley ME, et al. Further studies of elevated cerebrospinal fluid neuronal cell adhesion molecule in schizophrenia. Biol Psychiatry 1998; 43: 680-6.
188. Vawter MP, Hemperly JJ, Freed WJ, Garver DL. CSF N-CAM in neuroleptic-naïve first-episode patients with schizophrenia. Schizophr Res 1998; 34: 123-131.
189. Cremer H, Chazal G, Lledo PM, et al. PSA-NCAM: an important regulator of hippocampal plasticity. Int J Dev Neurosci 2000; 18: 213-20.
190. Cremer H, Lange R, Christoph A, et al. Inactivation of the N-CAM gene in mice results in size reduction of the olfactory bulb and deficits in spatial learning. Nature 1994; 367: 455-9.
191. Foley AG, Hirst WD, Gallagher HC, et al. The selective 5-HT6 receptor antagonists SB-271046 and SB-399885 potentiate NCAM PSA immunolabeling of dentate granule cells, but not neurogenesis, in the hippocampal formation of mature Wistar rats. Neuropharmacology 2008; 54: 1166-74.
192. Hasan A, Nitsche MA, Rein B, et al. Dysfunctional long-term potentiation-like plasticity in schizophrenia revealed by transcranial direct current stimulation. Behav Brain Res 2011; 224: 15-22.
193. West PJ, Marcy VR, Marino MJ, Schaffhauser H. Activation of the 5-HT(6) receptor attenuates long-term potentiation and facilitates GABAergic neurotransmission in rat hippocampus. Neuroscience 2009; 164: 692-701.
194. Bové J, Martínez-Vicente M, Vila M. Fighting neurodegeneration with rapamycin: mechanistic insights. Nature Rev Neurosci 2011; 12: 437-52.
195. Schenone S, Brullo C, Musumeci F, Biava M, Falchi F, Botta M. Fyn kinase in brain diseases and cancer: the search for inhibitors. Curr Med Chem 2011; 18: 2921-42.
196. Korb E, Finkbeiner S. Arc in synaptic plasticity: from gene to behavior. Trends Neurosci 2011; 34: 591-8.
197. Chin J, Palop JJ, Puoliväli J, et al. Fyn kinase induces synaptic and cognitive impairments in a transgenic mouse model of Alzheimer's disease. J Neurosci 2005; 25: 9694-703.
198. Hattori K, Fukuzako H, Hashiguchi T, et al. Decreased expression of Fyn protein and disbalanced alternative splicing patterns in platelets from patients with schizophrenia. Psychiatry Res 2009; 168: 119-28.
199. Ohnuma T, Kato H, Arai H, McKenna PJ, Emson PC. Expression of Fyn, a non-receptor tyrosine kinase in prefrontal cortex from patients with schizophrenia and its correlation with clinical onset. Mol Brain Res 2003; 112: 90-94.
200. Yun H-M, Kim S, Kim H-J, et al. The novel cellular mechanism of human 5-HT6 receptor through an interaction with Fyn. J Biol Chem 2007; 282: 5496-505.
201. Ca2+, ERK1/2 and Fyn kinase through a full activation of cloned human 5-HT6 receptors. Eur J Pharmacol 2011; 661: 8-14.
202. Yger M, Girault J-A. DARPP-32, Jack of All Trades… Master of Which? Front Behav Neurosci 2011; 5: 14.
203. Svenningsson P, Tzavara ET, Liu F, Fienberg AA, Nomikos GG, Greengard P. DARPP-32 mediates serotonergic neurotransmission in the forebrain. Proc Natl Acad Sci USA 2002; 99: 3188-93.
204. Kunii Y, Ikemoto K, Wada A, et al. Detailed DARPP-32 expression profiles in postmortem brains from patients with schizophrenia: an immunohistochemical study. Med Mol Morphol 2011; 44: 190-9.
205. Albert KA, Hemmings HC, Adamo AIB, et al. Evidence for decreased DARPP-32 in the prefrontal cortex of patients with schizophrenia. Arch Gen Psychiatry 2002; 59: 705-12.
206. Nairn AC, Svenningsson P, Nishi A, Fisone G, Girault J-A, Greengard P. The role of DARPP-32 in the actions of drugs of abuse. Neuropharmacology 2004; 47 (Suppl 1): 14-23.
207. ClinicalTrials.gov. A service of the U.S. National Institutes of Health 2013 [cited 2013 Aug 3]. Available from: http: //clinicaltrials.gov/
208. Froestl W, Muhs A, Pfeifer A. Cognitive enhancers (nootropics). Part 1: drugs interacting with receptors. JAlzheimers Dis 2012; 32: 793-887.
209. Codony X, Vela JM, Ramírez MJ. 5-HT(6) receptor and cognition. Curr Opin Pharmacol 2011; 11: 94-100.
210. Yun H-M, Rhim H. The serotonin-6 receptor as a novel therapeutic target. Exp Neurobiol 2011; 20: 159-68.
211. Keefe RSE, Buchanan RW, Marder SR, et al. Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far? Schizophr Bull 2013; 39: 417-35.
212. Buchanan RW, Keefe RSE, Umbricht D, Green MF, Laughren T, Marder SR. The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later? Schizophr Bull 2011; 37: 1209-17.
213. Kern RS, Gold JM, Dickinson D, et al. The MCCB impairment profile for schizophrenia outpatients: results from the MATRICS psychometric and standardization study. Schizophr Res 2011; 126: 124-31.
214. Pipeline: Products in development 2013.H. Lundbeck A/S [cited 2013 Aug 3]. Available from: http: //investor.lundbeck.com/pipeline.cfm
215. Product development pipeline 2013.GlaxoSmithKline [cited 2013 Aug 3]. Available from: http: //www.gsk.com/content/dam/gsk/globals/documents/pdf/GSK 2013 Pipeline.pdf
216. Liu KG, Robichaud AJ. 5-HT6 medicinal chemistry. In: Borisini F, Ed. Int Rev Neurobiol: Pharmacology of 5-HT6 receptors. Part 1. New York: Academic Press 2010; pp. 1-34.
217. Pfizer Pipeline.Pfizer [cited 2013 Aug 3]. Available from: http: //www.pfizer.com/sites/default/files/productpipeline/ pipeline_2013_0509.pdf
218. Comery T, Zasadny K, Morris E, et al. Receptor occupancy of the 5-HT6 receptor antagonist SAM-760 in non-human primates and healthy human volunteers. Alzheimer Dement 2011; 7 (Suppl): S794-5.
219. Bell J, Baird-Bellaire S, Leil T, et al. Single-and multiple-dose safety, tolerability and pharmacokinetics of a Novel 5HT6 receptor full antagonist (SAM-760) for the treatment of the symptoms of Alzheimer's disease in healthy young adults and elderly subjects. Alzheimer Dement 2011; 7 (Suppl): S778.
220. Study Evaluating The Safety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil . ClinicalTrials.gov Identifier: NCT01712074.Pfizer [cited 2013 Aug 3]. Available from: http: //clinicaltrials.gov/ct2/show/NCT01712074?term=NCT01712074& rank=1
221. A Positron Emission Tomography Study of SLV354 in Healthy Subjects and Subjects With Schizophrenia. ClinicalTrials.gov Identifier: NCT01545310.Abbott [cited 2013 Aug 3]. Available from: http: //clinicaltrials.gov/ct2/show/NCT01545310?term=SLV-354&rank=2
222. Safety, Tolerability and Pharmacokinetics of ABT-354 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors. ClinicalTrials.gov Identifier: NCT01908010.AbbVie[cited 2013 Aug 3]. Available from: http: //clinicaltrials.gov/ct2/show/NCT01908010?term=ABT-354&rank=1
223. Avineuro pipeline.Avineuro[cited 2013 Aug 3]. Available from: http: //www.avineuro.com/pipeline/
224. Positive top-line results from a Phase 2a clinical proof of concept trial to assess AVN-211 as an augmentation therapy to improve cognition in schizophrenia patients. Avineuro [cited 2013 Aug 3]. Available from: http: //www.avineuro.com/avineuropharmaceuticals-inc-reports-positive-phase-2a-clinical-proof-of concept-trial-results-on-avn-211-potent-small-molecule-fortreatment-of-schizophrenia/
225. Morozova MA, Lepilkina TA, Rupchev GE, et al. Add-on clinical effects of selective antagonist of 5HT6 receptors AVN-211 (CD-008-0173) in patients with schizophrenia stabilized on antipsychotic treatment: pilot study. CNS Spectr 2013; 17: 1-8.
226. Initiation of Phase 2b clinical studies of AVN-211, the best in-class, selective small molecule antagonist of 5-HT6 receptor for treatment of Schizophrenia. Avineuro[cited 2013 Aug 3]. Available from: http: //www.avineuro.com/avineuro-pharmaceuticals-incannounces-beginning-of-phase-2b-clinical-studies-of-avn-211-potent-small-molecule-for-treatment-of-schizophrenia/
227. SYN120 for the treatment of Alzheimer's disease and other cognitive disorders.Biotie Therapies [cited 2013 Aug 3]. Available from: http: //www.biotie.com/en/product_and_development/central_nervous_s ystem_disorders/syn120
228. Suven Discovery. Suven Live Sciences [cited 2013 Aug 3]. Available from: http: //www.suven.com/Pdf/Drug Discovery Collaboration Research and Services.pdf
229. Nirogi R, Kandikere V, Mudigonda K, et al. SUVN-502: A potent and selective 5-HT6 antagonist, potential drug for the treatment of Alzheimer's disease. Alzheimer Dement 2011; 7 (Suppl): S659.
230. Meyer U, Feldon J. Epidemiology-driven neurodevelopmental animal models of schizophrenia. Prog Neurobiol 2010; 90: 285-326.
231. Shobo M, Yamada H, Mihara T, et al. Two models for weight gain and hyperphagia as side effects of atypical antipsychotics in male rats: validation with olanzapine and ziprasidone. Behav Brain Res 2011; 216: 561-8.
232. Lindner MD, Hodges Jr DBH, Hogan JB, et al. An assessment of the effects of serotonin 6 (5-HT6) receptor antagonists in rodent models of learning. J Pharmacol Exp Ther 2003; 307: 682-91
233. Meyer-lindenberg A, Straub RE, Lipska BK, et al. Genetic evidence implicating DARPP-32 in human frontostriatal structure, function, and cognition. J Clin Invest 2007; 117: 672-82.